LigronBio

Drugging the undruggable with molecular glues to degrade harmful proteins, treating Alzheimer’s and other neurological disorders with unmet medical needs.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Murrieta, CA, USA
  • Currency USD
  • Founded October 2023
  • Employees 5
  • Incorporation Type C-corp
  • Website ligronbio.com

Company Summary

LigronBio is a biotechnology company developing molecular glues like, LIB-050, LIB-067, LIB-068 and LIB-076 to target and degrade harmful proteins linked to Alzheimer’s and other neurological disorders. Leveraging AI-powered technology and the body’s natural E3 ligase system, we aim to revolutionize treatment for diseases with unmet needs, with projected revenues of $3.3 billion from therapeutics and $110 million from diagnostics by 2034.

Team

  • Nataraj Pagadala
    Founder, President& CEO

    Hello, I’m Dr. Nataraj Pagadala, a scientist with 20+ years in drug discovery. I’ve worked on neurodegenerative and infectious diseases, including with Nobel laureate Dr. Houghton on Hepatitis C. I founded LigronBio to develop precision therapies for Alzheimer’s, cancer, and infectious diseases using AI-driven molecular glues targeting Raf-1.

  • Claudia Shojai
    Principal -Clinical Trail Operations

    Claudia Shojai, Principal – Clinical Trial Operations – Expert in clinical operations, regulatory compliance, and trial management. Skilled in IND submissions, FDA/EMA interactions, GxP compliance, and REDCap implementation. Her leadership will drive LigronBio’s ALS therapeutic development.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free